Orphan drug bill
S 2060 cosponsor Sen. Metzenbaum (D-Ohio) meets with Democratic presidential candidate Bill Clinton in Ohio July 20 during the candidate's "buscapade." Clinton reportedly is receptive to amending the Orphan Drug Act by adding a sales-based competition trigger to shorten market exclusivity. Metzenbaum staff meet July 22 with industry opponents of S 2060 -- including the Industrial Biotechnology Association, Amgen and Genentech -- to report that the senator is willing to wait until next year to enact his preferred bill with the support of a Democratic president but is also willing to move compromise legislation this year if opponents can come up with an alternative that includes the sales trigger. Industry groups believe they will continue to have House and Senate allies in opposing the trigger regardless of the election's outcome.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth